Autism

PaxMedica Announces Closing of $7.0 Million Public Offering

TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused…

1 year ago

Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals LLC (Yamo), a clinical stage pharmaceutical company, announced today that…

1 year ago

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing…

1 year ago

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for…

1 year ago

Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

A corporate workshop session will feature Dr. Alka Chaubey, Bionano’s chief medical officer, Dr. Panieh Terraf from Memorial Sloan Kettering…

1 year ago

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for…

1 year ago

Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)…

1 year ago

Circle Care Services Launches ABA Therapy for Children With Autism in Georgia

Circle Care Services expands into its third state to offer innovative behavioral therapy to children diagnosed with autism spectrum disorder.MARIETTA,…

1 year ago

Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan

Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering…

1 year ago

Bionano Announces Pricing of $80.0 Million Registered Offering and Concurrent Private Placement of Senior Secured Convertible Notes and Warrants

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0…

1 year ago